The brain plays an important role in the regulation of energy balance in higher animals. Global energy balance is monitored by sets of neurons in the hypothalamus that respond to peripheral hormonal and afferent neural signals that sense the energy status. Malonyl-CoA, an intermediate in the biosynthesis of fatty acids, appears to function in this hypothalamic energy-sensing system. The steady-state level of malonyl-CoA is determined by its rate of synthesis catalysed by ACC (acetyl-CoA carboxylase) relative to its rate of turnover catalysed by FAS (fatty acid synthase). Changes in the level of malonyl-CoA in the hypothalamus alter the expression/secretion of key hypothalamic orexigenic and anorexigenic neuropeptides that regulate the feeding behaviour and energy expenditure. Inhibitors of FAS, administered i.c.v. (intracerebroventricularly) to lean or obese mice, cause a rapid rise in hypothalamic malonyl-CoA level, suppression of food intake, increased fatty acid oxidation in skeletal muscle and profound weight loss. Stereotactic delivery of a viral MCD (malonyl-CoA decarboxylase) expression vector into the ventral hypothalamus lowers malonyl-CoA levels and reverses the anorectic effect of the FAS inhibitors. Fasting decreases, whereas refeeding increases, hypothalamic malonyl-CoA and alters subsequent feeding behaviour accordingly. The level of malonylCoA in the hypothalamus appears to be under the control of 5 -AMP kinase, which phosphorylates and thereby inactivates ACC under conditions of energy surplus. Thus malonyl-CoA appears to link the energyresponsive fatty acid synthesis in the hypothalamus to feeding behaviour and peripheral energy expenditure.
Introduction
The hypothalamus receives and processes hormonal and afferent neural signals that reflect the energy status of the animal. These signals trigger the expression and secretion of the orexigenic and anorexigenic neuropeptides that regulate food intake and energy expenditure. Most notable among these neuropeptides are the orexigens, NPY (neuropeptide Y) and AgRP (agouti-related peptide), and the anorexigens, POMC (pro-opiomelanocortin)/αMSH (α-melanocortinstimulating protein) and CART (cocaine-amphetamine-regulated transcript) [1, 2] . These neuropeptides are expressed by NPY/AgRP or POMC/CART neurons in the Arc (arcuate nucleus) of the hypothalamus and send projections to other regions of the hypothalamus including the PVN (paraventricular nucleus), LHA (lateral hypothalamic area), VMN (ventral medial nucleus) and DMH (dorsal medial hypothalamus). Second-order neurons from these regions project to higher brain centres where this information is integrated and behavioural responses are formulated [1] .
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The malonyl-CoA hypothesis
Our early studies on the effect of FAS (fatty acid synthase) inhibitors on food intake identified a linkage between the energy-responsive system of fatty acid synthesis in the hypothalamus and feeding behaviour and energy expenditure [3, 4] . Intraperitoneal administration of potent FAS inhibitors, i.e. cerulenin or the structurally related derivative C75, suppress food intake of both lean and obese mice causing profound weight loss ( Figure 1 ) [3, 5] . Moreover, the suppression of food intake is closely correlated to decreased expression of orexigenic neuropeptides (AgRP and NPY) and increased expression of anorexigenic neuropeptides (POMC/ αMSH and CART) in the hypothalamus [6] . Whether the inhibitors act centrally or peripherally was assessed by i.c.v. (intracerebroventricular) administration of low levels of C75. I.c.v. administration of C75 rapidly suppresses food intake in a dose-dependent manner [3, 7] . Consistent with its action in the central nervous system, C75 administered i.c.v. produces the same pattern of neuropeptide expression as occurs by i.p. (intraperitoneal) administration [7] . The site of the blockade by C75 appears to lie upstream of NPY in the signal transmission pathway, as its effect on food intake could be reversed by the i.c.v. injection of NPY [3] .
The possibility was considered that malonyl-CoA might serve as a mediator in the response to C75, first because inhibition of FAS would be expected to increase the level of its substrate (malonyl-CoA) and, secondly, because a precedent exists for malonyl-CoA as a mediator of fatty acid [8] . In the latter case, malonyl-CoA functions as a negative mediator of fatty acid oxidation under conditions of energy surplus by inhibiting CPT-1 (carnitine palmitoylCoA transferase-1), which blocks entry of fatty acids into the mitochondria for β-oxidation. Based on these facts and other findings [6, 7] , we formulated the 'malonyl-CoA hypothesis' (illustrated in Scheme 1). This hypothesis has a rational physiological basis. Metabolic flux through the pathway of fatty acid synthesis is responsive to changes in energy balance being active during times of nutrient surplus and inactive during nutrient deficit, e.g. the fasted state. Our most recent evidence (described below) validates this hypothesis.
Differential effects of FAS inhibitors on food intake of lean and obese mice
There is a striking difference in the response of lean versus obese mice to the FAS inhibitors [4] . After treating lean mice for 1 day with C75, the mice become refractory to subsequent injections of the FAS inhibitor. Moreover, lean mice treated with C75 for several days exhibit a marked rebound hyperphagia following cessation of treatment. In contrast, obese (ob/ob or high fat-fed) mice are more responsive to C75 exhibiting an approx. 90% suppression of food intake. Furthermore, the response of obese mice to C75 is not transient. Rather, decreased food intake and body mass continues for at least 1 month of repetitive injections of C75. During this period the decrease in body mass is profound approaching that of lean mice after a month ( Figure 1 ) [5] . It should be noted that the weight loss by obese mice is due almost entirely to the loss of body fat [4] .
Effect of FAS inhibitors on energy expenditure
To assess the effect of FAS inhibitors on energy expenditure, paired feeding experiments were conducted in which the food intake of 'pair-fed' controls was restricted to, i.e. isocaloric with that of C75-treated mice [4] . Despite this caloric restriction, pair-fed mice lost much less body mass than mice treated with C75. These findings suggested that, in addition to the suppression of food intake, C75-treated mice also exhibited increased energy expenditure. Subsequent studies corroborated this assertion. The possibility was considered that a C75-induced thermogenic response might be responsible for the apparent increase in energy expenditure. First, it was found that central (i.c.v.) or peripheral (i.p.) administration of C75 rapidly up-regulated the expression of UCP3 (uncoupling protein 3) in skeletal muscle [5] (S.-H. Cha and M.D. Lane, unpublished work). Thus the C75 signal, which alters hypothalamic neuropeptide expression, is rapidly ( 2 h) transmitted (probably via the sympathetic nervous system) to skeletal muscle, where energy metabolism is affected. C75 also rapidly up-regulates the expression of PGC1α, a transcriptional co-activator for the PPAR-α (peroxisome-proliferator-activated receptor-α) and UCP3 genes (S.-H. Cha and M.D. Lane, unpublished work). These events correlate closely with the rapid activation of wholebody fatty acid oxidation ([ 14 C]oleic acid→ 14 CO 2 ) by i.c.v. C75 and fatty acid oxidation in vitro by muscle explants from mice given C75 by i.c.v. injection (S.-H. Cha and M.D. Lane, unpublished work). As expected, indirect calorimetry showed that administration of C75 to obese mice (produced by feeding a high-fat diet) increases O 2 consumption [9] . Together, these findings provide convincing evidence that centrally administered C75 not only suppresses food intake, but also increases energy expenditure. It appears likely that the energy expenditure effect is the result of increased rate of fatty acid oxidation by skeletal muscle, since centrally administered C75 rapidly activates the expression of PGC1α and UCP3 and of [
14 C]oleic acid → 14 CO 2 in this tissue. The fact that the effect is rapid ( 2.5 h) suggests that the response is neurally transmitted, presumably from the central nervous system via the sympathetic nervous system.
Effect of FAS inhibitors on the activity of hypothalamic neurons
The expression of c-Fos is an accepted indicator of neuronal activation. As the result of a 24 h fast, neuronal activation of c-Fos expression is markedly increased in regions of the hypothalamus that are known to be involved in the regulation of feeding behaviour, notably the Arc, LHA and PVN [10] . This pattern of neuronal activation reflects hunger and correlates with a decreased hypothalamic malonyl-CoA (discussed above), coupled with increased expression of orexigenic neuropeptides and decreased expression of anorexigenic neuropeptides (see below) in the hypothalamus. The i.c.v. administration of the FAS inhibitor, C75, to lean mice rapidly ( 2 h) inhibits fasting-induced increase in c-Fos expression in the Arc and PVN and suppresses food intake [10] , despite the fact that C75 itself suppresses food intake. Recently, it was found that the neurons inactivated by C75 (as indicated by the expression of c-Fos) are orexigenic NPY/AgRP neurons [10] .
Effect of FAS inhibitors on the expression of hypothalamic neuropeptides that regulate feeding behaviour
The expression of the orexigenic and anorexigenic neuropeptides is inversely affected by FAS inhibitors in lean or obese mice when assessed 24 h after inhibitor administration [6] . Thus a single i.p. injection of C75 down-regulates the orexigenic neuropeptides, NPY and AgRP, while up-regulating the anorexigenic neuropeptides, CART and POMC/ αMSH, in the hypothalamus. Associated with these changes in neuropeptide expression is the complete suppression of food intake and substantial weight reduction.
Similarly, central administration of C75 rapidly altered the expression of the same set of hypothalamic neuropeptides [7] . Following a 23 h fasting, C75 was administered by i.c.v. injection after which either the mice were offered food or fasting was continued for an additional 2 h. Fasting itself caused a >2-fold increase in the expression of NPY and AgRP and a >2-fold decrease of the expression of POMC/ αMSH and CART. Refeeding promptly ( 2 h) reversed these changes. In contrast, the central administration (i.c.v.) of C75 to fasted mice provoked changes in the opposite direction, i.e. NPY and AgRP decreased >2-fold, while POMC/αMSH and CART increased approx. 2-fold. These changes in neuropeptide expression and suppression of food intake were also rapid (<2 h), despite the fact that the C75-treated mice were, in effect, in a 'fasted' state. It can be concluded that i.c.v. C75 blocks the fasting-induced changes in expression of the orexigenic and anorexigenic neuropeptides. Since i.c.v. C75 also causes a rapid ( 2.5 h) increase in hypothalamic malonylCoA concentration (see below) under the same conditions, it appeared that an increase in malonyl-CoA concentration was responsible for the observed changes in expression of the hypothalamic orexigenic and anorexigenic neuropeptides.
Changes in hypothalamic malonyl-CoA concentration affect feeding behaviour
Validation of the malonyl-CoA hypothesis requires accurate measurement of hypothalamic malonyl-CoA concentration. As the amount of hypothalamic tissue is quite small (∼10 mg/ mouse hypothalamus), the usual enzymatic methods for quantifying malonyl-CoA are not sufficiently sensitive. Therefore an ultra-sensitive assay system was developed to circumvent this limitation. In this analysis, the CoA moiety from malonyl-CoA is repetitively recycled thereby increasing the sensitivity of the analysis >1000-fold [7] . Using this methodology, hypothalamic [malonyl-CoA] was found to closely correlate with the physiological state being low when mice were fasted and rapidly ( 2 h) increasing 4-5-fold following refeeding [7] . These findings confirmed the hypothesis that the FAS inhibitor, C75, which inhibits FAS blocks the turnover of malonyl-CoA in vivo. Thus the central (i.c.v.) administration of C75 rapidly ( 2 h) caused a >4-fold increase in hypothalamic malonyl-CoA and an immediate suppression of food intake [7] .
The malonyl-CoA hypothesis (Scheme 1) predicts that suppression of food intake caused by a C75 blockade of FAS and the resulting increase in hypothalamic [malonylCoA], should be reversed by inhibition of malonyl-CoA formation with an ACC (acetyl-CoA carboxylase) inhibitor, such as TOFA. This was found to be the case [7] . Thus TOFA, administered i.c.v. before C75, prevented both the C75-induced increase in hypothalamic [malonyl-CoA] and the associated decrease of food intake. Taken together, these findings provide compelling evidence that the level of hypothalamic malonyl-CoA, which depends on the relative activities of ACC and FAS, is an indicator of energy status and mediates feeding behaviour.
An independent approach was used to verify these findings. To lower the malonyl-CoA level in neurons in the critical feeding centres, an MCD (malonyl-CoA decarboxylase) viral expression vector was delivered by stereotactic injection into the ventral region of the hypothalamus (Scheme 2) (Y. Dai, Z. Hu and M.D. Lane, unpublished work). Delivery into the ventral hypothalamus was verified by identical stereotactic injections of a control viral expression vector that encoded β-galactosidase followed by immunocytochemical staining of brain sections. The injections of the MCD viral vector led to small, but consistent, increases in food intake and body mass over the next 10 days. Remarkably, the MCD expression vector completely prevented the acute inhibition of food intake caused by centrally administered (i.c.v.) C75, 
Discussion
Multiple lines of evidence indicate that there is a link between fatty acid synthesis in hypothalamic neurons and feeding behaviour and energy expenditure. From a metabolic perspective, fatty acid synthesis occurs only during periods of energy surplus when physiological fuels are abundant. Under these conditions, metabolites are channelled into energy-storage pathways, circumstances down-regulate the orexigenic neuropeptides (NPY and AgRP) and up-regulate the anorexigenic neuropeptides (POMC/αMSH and CART) in the hypothalamus. These neuropeptides comprise a critical part of the system in the hypothalamus that monitors and responds to changes in energy balance [13] . The enzymes ACC and FAS, which catalyse fatty acid synthesis, are present in a subset of hypothalamic neurons [14] including those in the Arc [10] , a major site of expression of orexigenic and anorexigenic neuropeptides. Relevant to this report, the catalytic activity of ACC, which produces malonyl-CoA the substrate for FAS, is down-regulated when energy expenditure exceeds for example that in the fasted state. Under these conditions, the hypothalamic concentration of malonyl-CoA decreases [7] . Conversely, when fasted mice are re-fed, hypothalamic malonyl-CoA rapidly increases. The fact that administration of C75 by i.c.v. injection provokes a rapid increase in hypothalamic malonyl-CoA and blocks food intake suggests a causal relationship. Consistent with this view, an inhibitor of ACC, TOFA, which should prevent malonyl-CoA formation, blocks the increase in malonylCoA level and prevents the suppression of food intake provoked by C75. The fact that these changes are inversely correlated lends credence to the 'malonyl-CoA hypothesis' (Scheme 1). Finally, the stereotactic delivery of a viral MCD expression vector into the ventral hypothalamus, which lowers malonyl-CoA, also reverses the anorectic effect of FAS inhibitors, such as C75. While these lines of evidence show clearly that physiological and pharmacological perturbations that alter hypothalamic malonyl-CoA concentration also alter neuropeptide expression and thereby feeding behaviour, the molecular mechanism(s) by which malonyl-CoA triggers these events is not known.
